![Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis | Nature Reviews Neurology Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis | Nature Reviews Neurology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41582-019-0170-8/MediaObjects/41582_2019_170_Fig1_HTML.png)
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis | Nature Reviews Neurology
Testimony: Steffany Stern, Vice President of Advocacy, National Multiple Sclerosis Society Chairman Wyden, Ranking Member Crapo,
![Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download](https://images.slideplayer.com/36/10609964/slides/slide_2.jpg)
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
![Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2e3cbd4e-6095-448f-9448-b8a3500cabab/gr1.gif)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial - The Lancet Neurology
![Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021 Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021](https://pharma.nridigital.com/pharma/pharma_feb21/teva_medincell_lai_schizophrenia/1118760/__screenshot.jpg)
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
![Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download](https://slideplayer.com/10609964/36/images/slide_1.jpg)